SEK298.20
10.13% yesterday
Stockholm, Nov 15, 05:29 pm CET
ISIN
SE0000872095
Symbol
SOBI
Sector
Industry

Swedish Orphan Biovitrum Stock price

SEK298.20
+2.00 0.68% 1M
+10.40 3.61% 6M
+31.20 11.69% YTD
+52.00 21.12% 1Y
+68.20 29.65% 3Y
+138.65 86.90% 5Y
+212.20 246.74% 10Y
Stockholm, Closing price Fri, Nov 15 2024
-33.60 10.13%
ISIN
SE0000872095
Symbol
SOBI
Sector
Industry

Key metrics

Market capitalization SEK113.95b
Enterprise Value SEK131.24b
P/E (TTM) P/E ratio 32.21
EV/FCF (TTM) EV/FCF 20.65
EV/Sales (TTM) EV/Sales 5.16
P/S ratio (TTM) P/S ratio 4.48
P/B ratio (TTM) P/B ratio 3.07
Revenue growth (TTM) Revenue growth 19.59%
Revenue (TTM) Revenue SEK25.44b
EBIT (operating result TTM) EBIT SEK5.78b
Free Cash Flow (TTM) Free Cash Flow SEK6.35b
Cash position SEK594.00m
EPS (TTM) EPS SEK10.30
P/E forward 32.44
P/S forward 4.49
EV/Sales forward 5.17
Show more

Is Swedish Orphan Biovitrum a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Swedish Orphan Biovitrum Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Swedish Orphan Biovitrum forecast:

9x Buy
64%
4x Hold
29%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Swedish Orphan Biovitrum forecast:

Buy
64%
Hold
29%
Sell
7%

Financial data from Swedish Orphan Biovitrum

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
25,436 25,436
20% 20%
100%
- Direct Costs 9,093 9,093
20% 20%
36%
16,343 16,343
19% 19%
64%
- Selling and Administrative Expenses 3,489 3,489
8% 8%
14%
- Research and Development Expense 3,325 3,325
29% 29%
13%
9,529 9,529
30% 30%
37%
- Depreciation and Amortization 3,745 3,745
32% 32%
15%
EBIT (Operating Income) EBIT 5,784 5,784
29% 29%
23%
Net Profit 3,514 3,514
27% 27%
14%

In millions SEK.

Don't miss a Thing! We will send you all news about Swedish Orphan Biovitrum directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The firm focuses on the hematology and immunology therapeutic areas. It also offers specialty treatments in the area of genetics and metabolism. The company was founded in 2001 and is headquartered in Solna, Sweden.

Head office Sweden
CEO Guido Oelkers
Employees 1,772
Founded 2001
Website www.sobi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today